The oligodendrocyte-type-2 astrocyte lineage (O-2A) comprises a progenitor cell that is able to differentiate into an oligodendrocyte or astrocyte in vitro. The lineage was originally identified in the neonatal rat central nervous system but evidence suggests that the equivalent O-2A lineage also exists in humans. Apart from its putative and widely studied role in glial repair, this cell type could potentially be involved in malignant glioma formation. In this study we demonstrate that a rat O-2A progenitor cell line carrying the bacterial β-galactosidase reporter gene and transformed with the c-myc and H-ras oncogenes which has lost its differentiation capacity in vitro generates gliomalike growth after stereotactic injection into the adult rat brain. 
Introduction
The oligodendrocyte-type-2 astrocyte (O-2A) lineage was identified in the early 1980s from studies on one of the simplest central nervous system tissues, perinatal rat optic nerves (1) . From this tissue, which comprises mainly glial cells, a progenitor cell was identified that gave rise to oligodendrocytes and type-2 astrocytes (1,2). Many studies have been carried out on the factors that regulate O-2A differentiation and growth for both arms of the differentiation pathway (3) (4) (5) (6) , although there is still much controversy regarding the existence of the type-2 astrocyte. Further studies have identified an adult form of the O-2A progenitor, O-2A adult , which differs from the perinatal form in several ways. These differences include morphology, cell cycle time, migration time and differentiation properties (7) (8) (9) . This cell type is believed to proliferate in the adult brain (10) .
It is very likely that the O-2A progenitor cell is not restricted to the rodent. An O-2A-like progenitor cell has been identified from cultures of human fetal brain (11) and human embryonic spinal cord (12) . Recently it has been proposed that the O-2A progenitor cell is not restricted to the embryo. A proliferative adult human oligodendrocyte progenitor has been identified from dissociated normal brain tissue (13, 14) and cells identified with markers typical for progenitor cells in patients with multiple sclerosis (15) . These data suggest progenitor cells exist in adult human tissue. Thus it is possible that the O-2A progenitor cell is a target for transformation and the subsequent generation of glioma.
Recently we generated a series of rat O-2A cell lines by retroviral infection with a panel of oncogenes. One cell line expressing c-myc differentiated in a similar manner to primary O-2A cells into oligodendrocytes and astrocytes (16) . This cell line was superinfected with multiple copies of H-ras, resulting in the O-2A/c-myc/H-ras progenitor cell line, which was not able to differentiate regardless of culture conditions (16) . These cells maintained their progenitor antigenic phenotype in all three culture conditions which normally induce differentiation. Although the O-2A/c-myc/H-ras cell line was generated from neonatal (P7) rat optic nerve tissue, the resulting cell line expressed some of the characteristics of the adult progenitor cell (O4 expression and long-term maintenance in culture). It has been proposed from in vitro studies that adult progenitor cells are derived directly from a sub-population of perinatal O-2A progenitors (17) , thus leading to the possibility that the O-2A/c-myc cell line contains adult-like O-2A progenitor cells. This is of relevance, as we are proposing that the adult O-2A cell could be a target for transformation in brain tumours.
Using both these cell lines (O-2A/c-myc and O-2A/c-myc/ H-ras) we have identified a DNA-binding complex in O-2A progenitor cells, termed APprog, which disappears on differentiation into oligodendrocytes or astrocytes. Interestingly, in the O-2A/c-myc/H-ras progenitor cells, which are inhibited from differentiating, APprog is present continuously regardless of the culture conditions, illustrating an inverse link between APprog and differentiation (18) .
Apart from its putative and widely studied role in glial repair (for a review see ref. 19 ), the O-2A progenitor cell could potentially be involved in malignant glioma formation, being a target for the series of genetic changes that lead to transformation, especially as it is not a post-mitotic cell (20) . Glioblastomas, the most malignant glioma, can arise as a result of transformation of a pre-existing low-grade glioma (summarized in Figure 1 ) [e.g. astrocytoma, oligoastrocytoma and oligodendroglioma (21) ; WHO classification (22) ]. It is believed that most gliomas, in particular diffusely infiltrating astrocytomas, have an inherent tendency to progress towards a less differentiated, more malignant phenotype. The develop- ment of glioblastoma has been associated with modifications of many cellular constituents, e.g. p53, p16, epidermal growth factor (EGF) receptor and PDGFα receptor and also chromosomal rearrangements on 17, 19, 10 and 22 (23) (24) (25) (26) (27) .
The purpose of this study was to address whether the adult human O-2A progenitor cell could be a target for transformation by assessing the ability of a clonal population of rat O-2A progenitor cells to grow in the rat brain. The resulting pathology is compared with the WHO classification for human glioblastoma. In addition, a panel of human glioma cell lines are assessed for the presence of APprog, known to be present in O-2A progenitors and which strongly correlates with disrupted differentiation properties. It is hoped that, with a greater understanding of the origin of glioblastoma, appropriate therapies can be designed to target the malignant cells.
Materials and methods

Cell lines
The O-2A/c-myc/H-ras cell line was maintained in a modified version of defined Dulbecco's modified Eagle's medium (DMEM), referred to as Sato medium or DMEM-BS (28), containing 5 ng/ml both basic fibroblast growth factor (bFGF; Precision, Suffolk, UK) and platelet-derived growth factor (PDGF; R&D Systems, Abingdon, UK) on poly-L-lysine (13 µg/ml, mol. wt 100 000; Sigma, Poole, UK)-coated tissue culture flasks (Nunc). These two growth factors promote self-renewal of O-2A progenitor cells while inhibiting their differentiation (4) . Cells were fed daily with bFGF and PDGFAA and every other day half of the medium was removed and replaced with fresh DMEM-BS. To prepare the cells for injection, confluent 75cm 2 flasks of cells were treated with trypsin and resuspended in a 50:50 mixture of Hams F10 (Sigma) and DMEM (Gibco BRL, Paisley, UK) supplemented with 10% fetal calf serum (FCS; Gibco BRL) and 1% glutamine (Gibco BRL). Cells were pelleted by spinning in a centrifuge at 1000 r.p.m. for 5 min. The supernatant was removed and excess medium removed from the universal tube using sterile cotton buds. An aliquot of 20 µl fresh medium was gently mixed into the cell pellet to form a thick cell slurry. The cell slurry was taken up into a Hamilton syringe fitted with a 23G needle ready for in vivo injection.
The human glioma cell lines Ln-8, SB18 and T982G (from ECACC, Salisbury, UK) were maintained in DMEM supplemented with 10% FCS in tissue culture flasks. Primary cells Schwann cells. Sciatic nerves were taken from P1 day Sprague-Dawley rats and chopped up into small pieces. The tissue was enzymatically digested 1530 using previously described methods (1, 7, 16) . Cells were plated into 25cm 2 flasks and grown in DMEM containing 10% FCS. Schwann cells were enriched by a differential trypsinization procedure, which allowed the Schwann cells to be removed from the flask, leaving the majority of fibroblasts behind. Cell lysates were prepared for gel mobility shift assay as previously described (18) .
Cerebellum granule neurons. Cerebellum were taken from neonatal SpragueDawley rats. The meninges were removed and the tissue was chopped up into small pieces and enzymatically digested with 0.25% trypsin for 10 min. The resulting cell suspension was triturated and spun through a 3 ml cushion of 4% bovine serum albumin in 10% FCS at 1000 r.p.m. for 5 min. The resulting cells were resuspended in DMEM containing 10% FCS and plated into a 175 cm 2 flask coated with 10ϫ poly-L-lysine (13.3 µg/ml) for 15-30 min. The flask was then gently agitated. The supernatant contained enriched neurons. These cells were plated into a 75 cm 2 flask and a lysate prepared (18) .
Type-1 astrocytes. Cortical astrocytes were prepared as previously described (1) and a lysate prepared (18) .
Stereotactic injection
Adult male Sprague-Dawley rats (Harlan UK, Oxford, UK) weighing 250 g were anaesthetized using halothane (Rhone Morieux, Harlow, UK). The skull area was shaved and washed with a solution of chlorhexidine. The animal was placed in a Kopf stereotactic frame (Clarke Electromedical, Reading, UK) and a midline incision made in the scalp. The underlying area was cleared of tissue. A burr hole was made 3 mm to the right of the saggital suture and 1 mm caudal of the coronal suture using a Casali Milano dentist drill (Wright Dental Group, Dundee, UK) fitted with a stainless steel burr (size 016). The needle was advanced 6 mm from the top of the animal's skull into the brain and then raised to 4 mm, creating a pocket for the injected cells. A sample of 10 µl cell suspension was slowly injected; the needle was left in place for 1 min before being slowly withdrawn. Any reflux was removed to prevent formation of s.c. tumour growth. Surgicel (1ϫ1 cm) was placed over the burr hole prior to closing the wound with Dexon 3/0 metric sutures (Davis & Geck, St Louis, MO). Animals were weighed daily and killed on day 21 or earlier if weight loss reached 20%. Transcardial perfusion with heparinized saline followed by 10% formol saline was carried out under terminal anaesthesia and brains were carefully removed for pathological analysis. Brains to be stained with X-Gal were perfused with 0.2% paraformaldehyde, 2 mM MgCl 2 , 1.25 mM EGTA in 0.1 M PIPES buffer, pH 6.9, and the brains post-fixed in 25 ml of this buffer for 2 days prior to a wash in phosphate-buffered saline. (32, 34) .
Antibodies
The following antibodies were used to immunolabel either cryostat sections of rat brain or paraffin-embedded tissue. MRC OX-1 (1:100, anti-mouse IgG; Serotec) recognizes a monomorphic determinant on the rat leukocyte common antigen. MRC OX6 (hybridoma supernatant, 1:1) detects the I-A locus and for paraffin sections the antibody worked best after treatment with microwaves. ED1 (1:100, anti-mouse IgG; Serotec, Oxford, UK), which required microwave treatment, recognizes a glycoprotein expressed on myeloid cells. CD79a (1:50, anti-mouse IgG1; Dako, Cambridge, UK), which required microwave treatment, is a B cell marker. O4 was also used in paraffin sections (IgM, hybridoma supernatant, neat). For immunolabelling of all paraffin sections the secondary antibodies were absorbed against rat serum proteins [anti-mouse IgM and anti-mouse IgG (HϩL); Jackson ImmunoResearch Laboratories, PA].
Immunolabelling of paraffin sections
After fixation the samples were processed for paraffin embedding following standard procedures. Six micron sections were cut, dried in a 37°C incubator, dewaxed in xylene and rinsed in absolute alcohol, followed by incubation in 100% methanol and 3% hydrogen peroxide for 30 min to remove endogenous hydrogen peroxidase. Lastly, the sections were rinsed in water. We found that the optimal staining profile was obtained by microwaving the section twice for 5 min at full power (850 W) in citrate buffer, pH 6.0, followed by a blocking step for 10 min in phosphate-buffered saline containing 2% bovine serum albumin prior to an overnight incubation in primary antibody at 4°C. The sections were washed in phosphate-buffered saline three times over 30 min, followed by the appropriate secondary antibody. Antibodies were visualized with either anti-mouse Ig conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories) or using a biotin-labelled anti-mouse IgG followed by avidin:biotinylated horseradish peroxidase macromolecular complex (Vectorstain ABC kit; Vector Laboratories, Burlingame). For dual immunolabelling of the paraffin sections the hierarchy of chromophore application was diaminobenzamidine (DAB) with metal enhancer (cobalt chloride), giving a black coloration, prior to DAB, which gives a brown coloration, before the Vector VIP kit, which gives a purple coloration.
5-Bromo-4-chloro-3-indolyl β-D-galactoside (X-Gal) staining
After fixation, 50 µm brains sections were cut on a freezing microtome and placed into wells of a 24-well plate containing 1 mg/ml X-Gal solution (4 mg/ml stock dissolved in dimethylformamide) dissolved in 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 ·3H 2 O, 2 mM MgCl 2 , 0.01% sodium desoxycholate and 0.02% NP40. Sections were placed on gelatine-coated slides (dipped in 1% gelatine, 70% ethanol), air dried and dehydrated through alcohol, cleared in histoclear and mounted with DPX.
Immunolabelling of cryostat sections
Frozen cryostat sections were cut and kept moist. They were incubated with primary antibody overnight at 4°C, washed four times in staining solution (DMEM containing 1 mM HEPES, 5% donor calf serum, 0.05% sodium azide), incubated in secondary antibody for 2 h at room temperature, mounted in a drop of 2.5% 1,4-diazabicyclo-2.2.2 octane (Sigma, Poole, UK) to delay fading of fluorescein and sealed with nail varnish. Cultures were viewed on a Zeiss Axiophot microscope equipped with phase contrast and epi-UV illumination and selective filters for fluorescein and rhodamine.
Gel mobility shift assay
Incubations were carried out in 30 µl final volume as previously described (18) . Aliquots of 25 µg cell extract (volume adjusted with binding buffer: 10ϫ stock, 1 M HEPES, 0.5 M EDTA, 4 M NaCl, 50 mM phenylmethylsulphonyl fluoride, 10% bovine serum albumin, 0.4% glycerol) were incubated with 0.5 µl poly(dI·dC) (1 mg/ml), 0.15 µl/ml DTT (1 M) and 1 µl 32 Plabelled oligonucleotide on ice for 30 min. Samples were then loaded on a 4% TBE (0.09 M Tris, 0.09 M boric acid, 5 mM EDTA) acrylamide gel, electrophoresed at 150 V at 4°C for 2 h, fixed in 10%:10% (v/v) methanol:acetic acid, dried and exposed to Fuji X-ray film. Antibody addition experiments were carried out as described above, except that the lysates were pre-incubated with 2 µl antibodies to c-Jun and c-Fos (sc-447 and sc-822; Santa Cruz, Santa Cruz, CA) for 30 min on ice before addition of the labelled oligonucleotide (18) .
UV cross-linking UV cross-linking experiments to estimate the molecular weight of the individual components of APprog complexes used a derivative of the glial fibrillary acidic protein (GFAP)/activator protein-1 (AP-1) oligonucleotide synthesized with bromodeoxyuridine (BrdU) in place of thymidine, thus conferring increased susceptibility to UV-induced protein-DNA cross-linking (35, 36) . The DNA binding reaction and gel electrophoresis were carried out as described above. The gel was then exposed to a UV transilluminator source at 4°C for 30 min and areas containing the DNA-binding complexes of interest cut from the gel. These gel pieces were soaked in SDS-PAGE sample buffer (50 mM Tris, 30% glycerol, 2.5% SDS, 2% mercaptoethanol and bromophenol blue) for 15 min at 37°C then turned through 90°and placed on top of the stacker of a 10% SDS-PAGE gel and the proteins electrophoresed from the gel pieces. After electrophoresis the gel was fixed in 10% acetic acid, 10% methanol for 10 min, dried for autoradiography and exposed to Fuji X-ray film.
Results
Incidence of tumour growth
A total of 50 animals were used over three experiments. Tumour growth was relatively fast, with tumours being detected at 21 days. In the first two experiments (15 and 20 animals respectively) inoculation was~5ϫ10 5 cells/animal and a tumour was present in 60% of rat brains. In the third experiment, using 15 animals, the inoculum was increased to 1-2ϫ10 6 cells/rat and a tumour grew in all of these animals. In this latter experiment tumour growth was not always visible in the brain prior to histological analysis and only became apparent after haematoxylin and eosin staining of paraffin sections. Animals remained well throughout the experiment, with weight loss becoming apparent in a few animals around 20 days. (Figure 2) . Expression of these markers was heterogeneous, ranging from faint to intense. When the O-2A/c-myc cells were grown in serum-free and serum-containing medium they differentiated into oligodendrocytes and astrocytes and, correspondingly, gained expression of myelin and astrocyte markers (16) . The O-2A/c-myc/H-ras cells can be identified only by the antibodies A2B5, O4 and anti-NG2 (Figure 2) . Description of haematoxylin and eosin stained sections of tumour Variable amounts of tumour were seen in the cerebral hemisphere ipsilateral to the site of inoculation. In the process of enlarging and spreading, the tumour had replaced and destroyed the grey and white matter, in many instances extending from the surface of the brain to the ventricles. At low magnification the tumour appeared to have relatively well defined boundaries, but at higher magnification it was clear that fingers of tumour extended beyond the main mass into adjacent brain tissue, often having a perivascular orientation, especially in the white matter tracts, including the corpus callosum. In some instances the tumour had extended along the needle track to present on the surface of the brain ( Figure 3A-C) .
Immunolabelling of O-2A/c-myc/H-ras progenitor cells in vitro
At high power magnification the tumour appeared to consist of two types of cells ( Figure 3A) . The first comprised interweaving bundles of cells with round to oval nuclei with finely stippled chromatin, scant cytoplasm and lacking processes (top right corner). Therefore, there was a high nuclear/cytoplasmic ratio. The second and more darkly staining component of the tumour consisted of round mononuclear cells that appeared as lymphocytes (bottom right corner). Often these consisted of sheets of cells intermingling with the more pale staining elements and also extending from the margin of the tumour mass into adjacent tissues along the line of blood vessels. Foci of necrosis were detected, around which were collections of round darkly staining cells ( Figure 3B ). There was an absence of endothelial hyperplasia. Figure 3C In contrast, the more darkly staining component of the tumour was immunolabelled in paraffin and cryostat sections using a variety of antibodies for macrophages (ED1), all sub-populations of leukocytes, including lymphocytes and mononuclear phagocytes (MRCOX1), mononuclear phagocytes (MRCOX6) and B cells (CD79A) (Figure 3D-G) . The immune response was particularly marked at the margins of the tumour, including in the meninges, the perivascular tissue and the choroid plexus. Labelling techniques indicated that in the majority of the animals between 50 and 70% of the tumour mass showed an immune response. Figure 3D Figure 3F illustrates moderate leukocyte infiltration on cryostat sections using OX1. Figure 3G illustrates a collection of macrophages in relation to blood vessels and foci of necrosis. In all sections ( Figure 3D-G) there was absence of tumour staining. However, triple and double immunolabelling of sequential sections using antibodies to T cells, macrophages and B cells showed areas that were not immunolabelled and clearly had the pathology of tumour cells (data not shown).
X-Gal staining of tumours
To unambiguously identify the presence of transplanted cells in the rat brain O-2A/c-myc/H-ras cells were infected with a retrovirus containing the reporter β-galactosidase gene. This is a bacterial gene that is not usually present in normal mammalian cells. Detection of cells expressing this gene can be carried out by incubating microtome tissue sections with the X-Gal substrate at 37°C, which is enzymatically converted to produce a blue coloration in the cells. The strong blue reaction corresponded with the pale staining element of the tumour described above ( Figure 3H ).
APprog may be an indicator of O-2A progenitor cells in human glioma
We have previously demonstrated by gel mobility shift assay that O-2A progenitor cells, but not oligodendrocytes nor astrocytes, contain a DNA-binding complex, termed APprog (18) . In order to assess the prevalence of APprog in other neural cell types we carried out gel mobility shift assays with a GFAP/APprog probe using lysates prepared from enriched cultures of Schwann cells, astrocytes and cerebellar granule neurons (Figure 4) . APprog was not prevalent in these cultures, although very weak bands were detected at the expected position of APprog on the gel that may be due to contaminating O-2A cells ( Figure 4A ). There was a strong presence of the components of AP-1 (Jun and Fos), confirmed by a supershift gel mobility shift assay (18) . Under these conditions a specific interaction between Jun and Fos antibodies and a component of the DNA-binding complex (AP-1) is indicated by disruption or further retardation (supershifting) of the protein-DNA complex ( Figure 4B ). These data show that Schwann cells, type-1 astrocytes and cerebellar granule neurons contain AP-1.
The presence of APprog in O-2A lineage cells correlated strongly with O-2A progenitor cells and not oligodendrocytes nor astrocytes. To try and identify the components of APprog we carried out cross-linking studies, which provided a characteristic profile of the proteins that comprise APprog (see scheme in Figure 5 ). These released seven protein spots from the three individual bands first identified in the gel mobility shift assay. To assess whether these proteins could be useful for identifying the cellular composition of human gliomas, cross-linking studies on a panel of established cell lines [Ln18, T98G, A172, D251, U87MG, LNZ308 and SB18 (7-41)] were carried out. These experiments demonstrated that the fastest migrating band ( Figure 5 , band 4) was a common band between these tumours ( Figure 6 ). This fastest migrating band was analysed in more detail in gel mobility shift assays using several cold oligonucleotides as controls. Using a singlestranded non-related GC-rich oligonucleotide (ssGC), its double-stranded product and the control double-stranded GFAP/AP-1 oligonucleotide, it was found that the lower band of APprog could be competed out with the ssGC competitor ( Figure 7 ). This suggests that the fastest migrating band is a 1533 non-specific single-stranded DNA-binding protein, since the GC oligonucleotide does not contain the known consensus sequence for APprog as described in our previous work (18) . When we examined this band in O-2A lineage cells it was present in the rapidly dividing progenitor cells but not the differentiated progeny (18) , suggesting that the single-stranded binding protein may have some specificity for rapidly dividing cells.
It seems, therefore, that the fastest migrating band of APprog is a single-stranded DNA-binding protein that is present in rapidly dividing cells which disappears in differentiated cells. All tumours tested expressed band 4 (three proteins of mol. wt~30,~38 and~68 kDa) and to some extent band 1 [Jun and Fos (18)]. However, there was a striking similarity in expression of the proteins which migrated at a slower rate ( Figure 6A, bands 2 and 3) between O-2A progenitor cells and the tumour Ln18 and to some extent SB18 clone 12, which may be due to O-2A progenitor cells present in these two tumours.
Discussion
In this study we described the growth of cells in the rat brain from a clonal population of rodent O-2A cells that were immortalized and transformed in culture, thus giving us the opportunity to directly identify the origin of the tumour. We show that although there is an inflammatory response to this model system due to using outbred rats, we could detect tumours by expressing a reporter gene in the cells. We also propose that the DNA-binding proteins originally detected in rat O-2A cells, APprog, may be an indicator of the cellular origin of a subset of human glioblastomas and that these adult progenitor cells may be a target for transformation.
Generation of tumour growth in the rat brain
It is well established that tumorigenic conversion of primary cells requires the complementary action of two oncogenes Fig. 5 . Scheme of the protein components of APprog from UV cross-linking studies. Three bands were detected on gel mobility shift assay (2-4). The fastest migrating band generated three proteins of mol. wt~68,~40 and 35 kDa. The middle migrating band generated two proteins of mol. wt 55-60 and~80 kDa and the slowest migrating band generated proteins of mol. wt~68 and~80 kDa. Band 1 is composed of Jun and Fos. (42-44). Cooperation can be defined as a situation in which a pair of oncogenes acting in concert can convert primary cells into an established tumorigenic cell line (44) . For example, primary cultures of rat embryo fibroblasts were not rendered tumorigenic by a single transfection with the ras oncogene alone, but required a second transfection with the cellular myc oncogene or the large T antigen (42) . In addition, it was demonstrated, using a neural transplantation model and retrovirus-mediated gene transfer, that ras and myc had a powerful complementary transforming effect on neural progenitors in vivo (45) . It was, therefore, predictable that the O-2A cell line transfected with c-myc followed by several copies of H-ras would result in a tumorigenic cell line. Furthermore, inhibition of differentiation of O-2A/c-myc/H-ras progenitor cells found in vitro correlated with their tumorigenic nature (16) .
To confirm that the abnormal cell growth detected in the rat brain was due to the injected transformed O-2A cells, we marked these cells with the β-galactosidase reporter gene. In this manner we detected transformed cells, but also an inflammatory component. Human brain tumours show variable levels of leukocyte infiltration at the time of biopsy or autopsy (46) and inflammatory components have been detected in other models of glioma (C6 and 9L). However, the majority of the inflammatory response detected in the rat brain was probably due to the outbred nature of Sprague-Dawley rats. To reduce the inflammatory response in future experiments we plan to use immunocompatible rats. For this purpose we have had the cell line haplotyped using a panel of 14 anti-class I-specific antibodies and FACS analysis (data not shown). The results demonstrated that the cell line was RT1 u ϫRT1 l . It is proposed that a F 1 cross between RT1 u and RT1 l parental rats (Lew/ Ola/Hsd, RT1 l with AO/Ola/Hsd, RT1 u ) would be an appropriate host for this rat model of glioblastoma.
WHO classification of tumours
The classification of CNS tumours has been made almost exclusively by surgical pathologists based on terminology Fig. 7 . Specificity of APprog. Using cold oligonucleotides it can be seen that the fastest migrating band of APprog can be competed out with a nonspecific ssGC probe, which suggests that this band is non-specific, although specificity exists in that these proteins disappear on differentiation.
relating to the presumed origins of the transformed cells and their morphology (for reviews see refs 21, 47) . The WHO classification of brain tumours distinguishes four major entities of astrocytic gliomas: pilocytic astrocytoma (WHO grade I), astrocytoma (WHO grade II), anaplastic (malignant) astrocytoma (WHO grade III) and glioblastoma multiforme (WHO grade IV). Oligodendrogliomas and mixed gliomas (with both oligodendroglial and astrocytic components) occur in lowgrade (WHO grade II) and malignant variants (WHO grade III). For example, the term astrocytoma refers to a diffusely infiltrating tumour composed of well differentiated neoplastic astrocytes and glioblastoma to a macroscopically relatively well circumscribed tumour that histologically is highly cellular with poorly differentiated oval, round or pleomorphic cells and the occasional multinucleated giant cell in varying combinations (48) . There is a large amount of controversy regarding a classification of gliomas based on morphology alone and so other indicators which define cellular composition of gliomas could further aid in their classification.
In the generation of this transformed O-2A/c-myc/H-ras progenitor cell line the origin of the target cell is known, since we enriched for O-2A progenitors in culture by the application of both bFGF and PDGF, growth factors known to prevent differentiation and promote progenitor cell self-renewal (4, 16) . In addition, the resulting cells were cloned by limited dilution. However, if we are to say that progenitor cells are the target for transformation in glioblastoma formation we need to compare the pathology of the resulting tumour with the known pathology of human gliomas using the WHO classification.
The pathology of the clonal transformed O-2A progenitor cells fulfilled many of the requirements of a glioblastoma (21, 22, 26) , namely highly cellular, with poorly differentiated, fusiform, round or pleomorphic cells, areas of necrosis and variability in GFAP expression. Although many glioblastomas are GFAP-positive, a proportion are GFAP-negative, which may reflect their non-astrocytic origins, comprising instead O-2A progenitor cells (which are GFAP-negative). Two criteria for glioblastoma were absent, e.g. occasional multinucleated giant cells and endothelial proliferation, but lack of these is 1535 typical of high-grade malignant astrocytoma. From these criteria it is difficult to definitively classify the O-2A tumour according to the WHO description, which may be simply due to the fact that we are applying a human histological typing to a rat tumour. However, it is clear that the O-2A tumour is of glial origin, due to its clonal nature, and shares some of the characteristics of both glioblastoma and high-grade astrocytoma.
APprog as a marker of O-2A progenitor cells in human gliomas
We have recently demonstrated that two DNA-binding complexes, AP-1 and a novel O-2A progenitor-specific DNAbinding protein, APprog, are strongly correlated with growth and differentiation of O-2A progenitor cells (19) . APprog is present in the progenitor cells, but absent from differentiated progeny; conversely, AP-1 is present in the differentiated progeny and absent in the progenitor cells. So expression of APprog reflects the progenitor phenotype. This identification of a characteristic protein profile which may lead to a diagnosis of the cellular composition of gliomas and perhaps identify future specific treatments is not novel and other examples exist, e.g. the use of high resolution proton nuclear magnetic resonance spectroscopy. This measures a characteristic spectrum of metabolites and has demonstrated that (i) cells of the central and peripheral nervous systems can be easily identified and distinguished from each other (49); (ii) spectra from different cell types are conserved across species and through transformation (50); and (iii) a raised phosphocholine:snglycero-3-phosphocholine (PCho:GPCho) ratio may serve as an indicator of multiple oncogenic lesions and malignancy (51).
It has not been possible to date to identify the protein components of APprog, although gel mobility supershift assays have shown that they do not contain members of the Jun, Fos and maf family of proteins (18) . In order to estimate the approximate molecular mass of the protein components of APprog complexes, gel mobility shift assays were performed using a derivative of the AP-1 oligonucleotide in which thymidine was substituted by BrdU, followed by UV crosslinking and a second SDS-PAGE electrophoresis step. APprog was initially thought to contain seven proteins (18) . For example, the most slowly migrating APprog complex ( Figure 5 , band 2) released a predominant species of~75-80 kDa, which was also present in the complex of intermediate mobility ( Figure 5, band 3) , although the latter complex also contained a unique species of~45 kDa. In contrast, the most rapidly migrating complex ( Figure 5 , band 4) released three unique species of~30,~38 and~68 kDa. In testing a panel of human gliomas only two gliomas, Ln-18 and SB18 clone 12, produced profiles with similar protein components to the rat O-2A progentior cells (bands 2 and 3), suggesting that their cellular origins may comprise O-2A-like progenitor cells. Both of these human tumours had properties that suggested they were not astrocytic and possibly were related to O-2A progenitor cells.
Ln18 is a tumour that is not typical of the majority of the established glioma cell lines, having a bipolar and tripolar morphology in culture and expressing Ia-like antigens (40) . Ia antigens have been shown to be induced on O-2A progenitor cells and astrocytes, but not oligodendrocytes (52) . The SB18 clone 12 model appears to share a similar band to Ln18 and O-2A progenitors. This tumour again has a spindle-like morphology in culture and expresses A2B5, a marker often used to define O-2A progenitor cells (53) .
O-2A progenitor cells as the candidate cell for transformation in a subset of human glioblastomas
The evidence in this study is compelling for the O-2A progenitor cell as a target for transformation and may account for a subset of glioblastomas that are GFAP-negative originating de novo (as O-2A progenitor cells are themselves GFAPnegative) (Figure 1) . The O-2A/c-myc/H-ras cells produced a similar pathology to glioblastomas which have been reported to develop de novo, i.e. without originating from a previous astrocytic tumour. This concept is supported by the fact that an established human glioma cell line has been identified that contains O-2A progenitor-like cells. This cell line was generated by culturing the tumour sample in conditioned medium from astrocytes rather than in serum-containing medium. With time in culture a cell grew out which morphologically and antigenically resembled an O-2A progenitor cell and was able to differentiate into an oligodendrocyte or an astrocyte, depending on the culture conditions (54) . In addition, various reports have identified a human O-2A progenitor cell (11) (12) (13) (14) . These data all provide support for the presence of an adult human progenitor cell that may be the target for transformation in glioma. This idea has also been proposed in a review by Linskey (47) .
In summary, we believe that O-2A progenitor cells are the target for transformation for a subset of glioblastoma. It may be possible to identify O-2A-like human tumours by carrying out gel mobility shift assays using the AP-1/GFAP oligonucleotide. We have found that this assay works just as well on homogenized tissue as on cultured cells (data not shown) and allows us to circumvent the selection pressures associated with the establishment of human glioblastoma cells in culture.
